Stand Glaukom: Gründe für immer noch führende Erblindung weltweit

Zusammenfassung

Glaukom ist eine der führenden Ursachen für irreversible Blindheit weltweit und wird oft als der „stille Dieb des Sehens“ bezeichnet, da es häufig ohne erkennbare Symptome fortschreitet, bis es zu erheblichem Sehverlust kommt. Mit geschätzten 76 Millionen Betroffenen im Jahr 2020 und einer Prognose von über 111 Millionen bis 2040 erfordert die globale Situation dringende Aufmerksamkeit. Der durch Glaukom verursachte Sehverlust ist irreversibel, aber größtenteils verlangsambar, was die Bedeutung der frühen Erkennung und Behandlung unterstreicht. Die Diagnose stellt erhebliche Herausforderungen dar, insbesondere aufgrund der asymptomatischen Natur der Krankheit und altersbedingter Risikofaktoren. Ungleichheiten in der Versorgung und der Zugang zu angemessenen Behandlungen sind weitere Hindernisse, die zu verzögerten Diagnosen führen. Frühzeitige Diagnosen und Interventionen sind entscheidend, um das Fortschreiten der Erkrankung zu verlangsamen, das verbleibende Sehvermögen zu schützen und die Lebensqualität der Betroffenen zu verbessern. Diese Maßnahmen sind besonders wichtig, um die psychologischen Auswirkungen und die Beeinträchtigung der täglichen Aktivitäten zu minimieren. Der Einsatz innovativer Technologien und gezielter Interventionen könnte dazu beitragen, die frühzeitige Erkennung und Behandlung von Glaukom zu verbessern und so das Risiko von irreversiblem Sehverlust zu verringern.

Schlüsselwörter

Glaukom - irreversible Blindheit - Frühdiagnose - Sehverlust

Publication History

Received: 25 October 2024

Accepted: 26 March 2025

Article published online:
24 July 2025

• References/Literatur

• 1 Davuluru SS, Jess AT, Kim JSB. et al. Identifying, Understanding, and Addressing Disparities in Glaucoma Care in the United States. Transl Vis Sci Technol 2023; 12: 18
• 2 Allison K, Patel D, Alabi O. Epidemiology of Glaucoma: The Past, Present, and Predictions for the Future. Cureus 2020; 12: e11686
• 3 Tham YC, Li X, Wong TY. et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 2014; 121: 2081-2090
• 4 Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90: 262-267
• 5 Kyari F, Abdull MM, Bastawrous A. et al. Epidemiology of glaucoma in sub-saharan Africa: prevalence, incidence and risk factors. Middle East Afr J Ophthalmol 2013; 20: 111-125
• 6 Manz KC, Mocek A, Hoer A. et al. Epidemiology and Treatment of Patients With Primary Open Angle Glaucoma in Germany: A Health Claims Data Analysis. J Glaucoma 2024; 33: 549-558
• 7 Wolfram C. The Epidemiology of Glaucoma – an Age-Related Disease. Klin Monbl Augenheilkd 2024; 241: 154-161
• 8 Stein JD, Kim DS, Niziol LM. et al. Differences in rates of glaucoma among Asian Americans and other racial groups, and among various Asian ethnic groups. Ophthalmology 2011; 118: 1031-1037
• 9 Schuster AK, Erb C, Hoffmann EM. et al. The Diagnosis and Treatment of Glaucoma. Dtsch Arztebl Int 2020; 117: 225-234
• 10 Finger RP, Fimmers R, Holz FG. et al. Incidence of blindness and severe visual impairment in Germany: projections for 2030. Invest Ophthalmol Vis Sci 2011; 52: 4381-4389
• 11 Mansouri K, Orgul S, Meier-Gibbons F. et al. Awareness about glaucoma and related eye health attitudes in Switzerland: a survey of the general public. Ophthalmologica 2006; 220: 101-108
• 12 Lee PP, Walt JG, Doyle JJ. et al. A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma. Arch Ophthalmol 2006; 124: 12-19
• 13 George R, Panda S, Vijaya L. Blindness in glaucoma: primary open-angle glaucoma versus primary angle-closure glaucoma-a meta-analysis. Eye (Lond) 2022; 36: 2099-2105
• 14 Burr JM, Mowatt G, Hernandez R. et al. The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation. Health Technol Assess 2007; 11: 1-190 iii–iv, ix–x
• 15 Dandona L, Dandona R, Srinivas M. et al. Open-angle glaucoma in an urban population in southern India: the Andhra Pradesh eye disease study. Ophthalmology 2000; 107: 1702-1709
• 16 Vijaya L, George R, Arvind H. et al. Prevalence of angle-closure disease in a rural southern Indian population. Arch Ophthalmol 2006; 124: 403-409
• 17 Ng WS, Agarwal PK, Sidiki S. et al. The effect of socio-economic deprivation on severity of glaucoma at presentation. Br J Ophthalmol 2010; 94: 85-87
• 18 Fraser S, Bunce C, Wormald R. Risk factors for late presentation in chronic glaucoma. Invest Ophthalmol Vis Sci 1999; 40: 2251-2257
• 19 Sukumar S, Spencer F, Fenerty C. et al. The influence of socioeconomic and clinical factors upon the presenting visual field status of patients with glaucoma. Eye (Lond) 2009; 23: 1038-1044
• 20 Krishnadas R. The many challenges in automated glaucoma diagnosis based on fundus imaging. Indian J Ophthalmol 2021; 69: 2566-2567
• 21 Hamid S, Desai P, Hysi P. et al. Population screening for glaucoma in UK: current recommendations and future directions. Eye (Lond) 2022; 36: 504-509
• 22 Schuster AK, Wagner FM, Pfeiffer N. et al. Risk factors for open-angle glaucoma and recommendations for glaucoma screening. Ophthalmologe 2021; 118: 145-152
• 23 Gupta P, Zhao D, Guallar E. et al. Prevalence of Glaucoma in the United States: The 2005–2008 National Health and Nutrition Examination Survey. Invest Ophthalmol Vis Sci 2016; 57: 2905-2913
• 24 Owusu-Afriyie B, Peter N, Ivihi F. et al. Barriers to the uptake of eye care services: A cross-sectional survey from rural and urban communities. PLoS One 2024; 19: e0308294
• 25 Shickle D, Griffin M. Why donʼt older adults in England go to have their eyes examined?. Ophthalmic Physiol Opt 2014; 34: 38-45
• 26 Lu SJ, Girgis S, Shah P. et al. Patient Experience and Barriers to the Visual Field Test for Glaucoma. J Glaucoma 2024;
• 27 Hennis A, Wu SY, Nemesure B. et al. Awareness of incident open-angle glaucoma in a population study: the Barbados Eye Studies. Ophthalmology 2007; 114: 1816-1821
• 28 McKean-Cowdin R, Wang Y, Wu J. et al. Impact of visual field loss on health-related quality of life in glaucoma: the Los Angeles Latino Eye Study. Ophthalmology 2008; 115: 941-948.e1
• 29 Lampert T, Hoebel J, Kroll LE. Social differences in mortality and life expectancy in Germany. Current situation and trends. J Health Monit 2019; 4: 3-14
• 30 Lampert T, Kroll LE, Kuntz B. et al. Health inequalities in Germany and in international comparison: trends and developments over time. J Health Monit 2018; 3: 1-24
• 31 Baker RS, Bazargan M, Bazargan-Hejazi S. et al. Access to vision care in an urban low-income multiethnic population. Ophthalmic Epidemiol 2005; 12: 1-12
• 32 Allison K, Patel DG, Greene L. Racial and Ethnic Disparities in Primary Open-Angle Glaucoma Clinical Trials: A Systematic Review and Meta-analysis. JAMA Netw Open 2021; 4: e218348
• 33 Coughlin SS, Vernon M, Hatzigeorgiou C. et al. Health Literacy, Social Determinants of Health, and Disease Prevention and Control. J Environ Health Sci 2020; 6: 3061
• 34 Berkman ND, Sheridan SL, Donahue KE. et al. Low health literacy and health outcomes: an updated systematic review. Ann Intern Med 2011; 155: 97-107
• 35 Martin MJ, Sommer A, Gold EB. et al. Race and primary open-angle glaucoma. Am J Ophthalmol 1985; 99: 383-387
• 36 Kang JH, Wang M, Frueh L. et al. Cohort Study of Race/Ethnicity and Incident Primary Open-Angle Glaucoma Characterized by Autonomously Determined Visual Field Loss Patterns. Transl Vis Sci Technol 2022; 11: 21
• 37 Gao XR, Chiariglione M, Choquet H. et al. 10 Years of GWAS in intraocular pressure. Front Genet 2023; 14: 1130106
• 38 Girkin CA, Nievergelt CM, Kuo JZ. et al. Biogeographic Ancestry in the African Descent and Glaucoma Evaluation Study (ADAGES): Association With Corneal and Optic Nerve Structure. Invest Ophthalmol Vis Sci 2015; 56: 2043-2049
• 39 Collins DW, Gudiseva HV, Trachtman B. et al. Association of primary open-angle glaucoma with mitochondrial variants and haplogroups common in African Americans. Mol Vis 2016; 22: 454-471
• 40 Singh RK, Smith S, Fingert J. et al. Machine Learning-Derived Baseline Visual Field Patterns Predict Future Glaucoma Onset in the Ocular Hypertension Treatment Study. Invest Ophthalmol Vis Sci 2024; 65: 35
• 41 Stuart KV, Khawaja AP. Genomics enabling personalised glaucoma care. Br J Ophthalmol 2023; 108: 5-9
• 42 Braithwaite T, Calvert M, Gray A. et al. The use of patient-reported outcome research in modern ophthalmology: impact on clinical trials and routine clinical practice. Patient Relat Outcome Meas 2019; 10: 9-24
• 43 Sotimehin AE, Ramulu PY. Measuring Disability in Glaucoma. J Glaucoma 2018; 27: 939-949
• 44 Tomomitsu MS, Alonso AC, Morimoto E. et al. Static and dynamic postural control in low-vision and normal-vision adults. Clinics (Sao Paulo) 2013; 68: 517-521
• 45 Diniz-Filho A, Boer ER, Gracitelli CP. et al. Evaluation of Postural Control in Patients with Glaucoma Using a Virtual Reality Environment. Ophthalmology 2015; 122: 1131-1138
• 46 Friedman DS, Freeman E, Munoz B. et al. Glaucoma and mobility performance: the Salisbury Eye Evaluation Project. Ophthalmology 2007; 114: 2232-2237
• 47 Bertaud S, Zenouda A, Lombardi M. et al. Glare and Mobility Performance in Glaucoma: A Pilot Study. J Glaucoma 2021; 30: 963-970
• 48 Ramrattan RS, Wolfs RC, Panda-Jonas S. et al. Prevalence and causes of visual field loss in the elderly and associations with impairment in daily functioning: the Rotterdam Study. Arch Ophthalmol 2001; 119: 1788-1794
• 49 Coleman AL, Cummings SR, Yu F. et al. Binocular visual-field loss increases the risk of future falls in older white women. J Am Geriatr Soc 2007; 55: 357-364
• 50 Sotimehin AE, Yonge AV, Mihailovic A. et al. Locations, Circumstances, and Outcomes of Falls in Patients With Glaucoma. Am J Ophthalmol 2018; 192: 131-141
• 51 Coleman AL, Cummings SR, Ensrud KE. et al. Visual field loss and risk of fractures in older women. J Am Geriatr Soc 2009; 57: 1825-1832
• 52 Klein BE, Moss SE, Klein R. et al. Associations of visual function with physical outcomes and limitations 5 years later in an older population: the Beaver Dam eye study. Ophthalmology 2003; 110: 644-650
• 53 Bramley T, Peeples P, Walt JG. et al. Impact of vision loss on costs and outcomes in medicare beneficiaries with glaucoma. Arch Ophthalmol 2008; 126: 849-856
• 54 McGwin jr. G, Mays A, Joiner W. et al. Is glaucoma associated with motor vehicle collision involvement and driving avoidance?. Invest Ophthalmol Vis Sci 2004; 45: 3934-3939
• 55 Tanabe S, Yuki K, Ozeki N. et al. The association between primary open-angle glaucoma and motor vehicle collisions. Invest Ophthalmol Vis Sci 2011; 52: 4177-4181
• 56 van Landingham SW, Hochberg C, Massof RW. et al. Driving patterns in older adults with glaucoma. BMC Ophthalmol 2013; 13: 4
• 57 Gilhotra JS, Mitchell P, Ivers R. et al. Impaired vision and other factors associated with driving cessation in the elderly: the Blue Mountains Eye Study. Clin Exp Ophthalmol 2001; 29: 104-107
• 58 Bhargava JS, Patel B, Foss AJ. et al. Views of glaucoma patients on aspects of their treatment: an assessment of patient preference by conjoint analysis. Invest Ophthalmol Vis Sci 2006; 47: 2885-2888
• 59 Zhang X, Olson DJ, Le P. et al. The Association Between Glaucoma, Anxiety, and Depression in a Large Population. Am J Ophthalmol 2017; 183: 37-41
• 60 Zhou C, Qian S, Wu P. et al. Anxiety and depression in Chinese patients with glaucoma: sociodemographic, clinical, and self-reported correlates. J Psychosom Res 2013; 75: 75-82